Lyell CMO reports 20,279-share equity stake
Lyell Immunopharma’s chief medical officer reported initial holdings of common stock, RSUs, and multiple option grants with long-dated expirations and time-based vesting.
Rhea-AI Filing Summary
Lyell Immunopharma, Inc. (LYEL) reported the initial equity holdings of its Chief Medical Officer, Jarrad Mattieu Aguirre. He holds 20,279 shares of Common Stock, including 14,451 restricted stock units (RSUs) that vest quarterly over thirty months following July 9, 2026, subject to continued service. He also holds three option awards to purchase Common Stock: options over 46,249 shares at $11.64 per share expiring February 12, 2035; 35,000 shares at $23.71 expiring February 9, 2036; and 15,000 shares at $19.20 expiring May 10, 2036, each subject to specified time-based vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Aguirre Jarrad Mattieu
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) F2 | -- | -- | -- |
| holding | Option (right to buy) F3 | -- | -- | -- |
| holding | Option (right to buy) F4 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 96,249 contracts (Direct);
Common Stock — 20,279 shares (Direct)
Footnotes (4)
- F1. Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: the RSUs vest quarterly over the thirty month period following July 9, 2026; in each case, subject to the reporting person providing service through the applicable vesting date.
- F2. 25% of the option shares vested on January 31, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.
- F3. 12.5% of the option shares will vest on August 9, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
- F4. 12.5% of the option shares will vest on November 11, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
Key Figures
Common Stock held: 20,279 shares
Restricted Stock Units (RSUs): 14,451 units
Option underlying shares at $11.64: 46,249 shares
+2 more
5 metrics
Common Stock held
20,279 shares
Directly held common stock as of the Form 3 reporting date
Restricted Stock Units (RSUs)
14,451 units
RSUs under the 2021 Equity Incentive Plan vesting quarterly over thirty months after July 9, 2026
Option underlying shares at $11.64
46,249 shares
Option (right to buy) at $11.64 per share expiring February 12, 2035
Option underlying shares at $23.71
35,000 shares
Option (right to buy) at $23.71 per share expiring February 9, 2036
Option underlying shares at $19.20
15,000 shares
Option (right to buy) at $19.20 per share expiring May 10, 2036
Key Terms
restricted stock units ("RSUs"), time-based vesting, Equity Incentive Plan, vesting date
4 terms
restricted stock units ("RSUs") financial
"Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
time-based vesting financial
"RSUs under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Equity Incentive Plan financial
"RSUs under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vesting date financial
"subject to the reporting person providing service through the applicable vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the LYEL Form 3 filing disclose about Jarrad Mattieu Aguirre’s ownership?
The Form 3 shows that Chief Medical Officer Jarrad Mattieu Aguirre holds 20,279 shares of Lyell common stock, including 14,451 RSUs, and several option grants over additional shares of common stock, all subject to time-based vesting conditions.
How many Lyell (LYEL) restricted stock units does the chief medical officer hold?
He holds 14,451 restricted stock units (RSUs) under Lyell’s 2021 Equity Incentive Plan. These RSUs vest quarterly over a thirty-month period following July 9, 2026, provided he continues to provide service through each applicable vesting date.
What common stock position is reported for the chief medical officer of LYEL?
He is reported as holding 20,279 shares of Common Stock directly. This amount includes 14,451 RSUs that will be settled in common stock as they vest over time, subject to continued service with Lyell Immunopharma.
What option grants on Lyell (LYEL) stock are reported in the Form 3?
The filing lists three option positions: options over 46,249 shares at $11.64 per share expiring February 12, 2035; 35,000 shares at $23.71 expiring February 9, 2036; and 15,000 shares at $19.20 expiring May 10, 2036, all subject to time-based vesting.
How do the LYEL option grants to the chief medical officer vest?
For 46,249 shares at $11.64, 25% vested on January 31, 2026, with the rest vesting in equal monthly installments over the next 36 months. The 35,000- and 15,000-share options each vest 12.5% on specified 2026 dates, then monthly over the following 42 months, subject to continued service.
Are the LYEL equity holdings of the chief medical officer direct or indirect?
All reported holdings, including 20,279 shares of common stock, the 14,451 RSUs, and the option positions over common stock, are listed as direct ownership in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
